STAB实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 22:47):

Stats
今日成交量	414.00
平均成交量	25 083.00
市值	49 991.00
EPS	$0 ( 2024-03-11 )
下一个收益日期	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-02-22	Chandrasekhar Satishchandran	Buy	0
2021-09-09	Saluck Randy S.	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-09	Barbarick Steve K	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-09	Verny Lea	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-28	Markvicka Taunia	Buy	100 000	Common Stock, par value $0.005 per share

INSIDER POWER
0.00
Last 70 transactions
Buy: 2 421 695 \| Sell: 3 004 967

Statera Biopharma, Inc. 相关性

10 最正相关
NAKD	0.946
BHTG	0.935
TUEM	0.935
LGMK	0.932
MTEX	0.93
GRIN	0.923
AMGN	0.918
PIII	0.917
SMIT	0.917
CREG	0.916

10 最负相关
ALGM	-0.974
ATRS	-0.966
QIPT	-0.965
FRSG	-0.965
XPDB	-0.963
ITAQ	-0.963
CRUS	-0.963
VPCB	-0.962
NPAB	-0.961
ACQR	-0.961

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Statera Biopharma, Inc. 财务报表

Annual	2021
营收:	$1.49M
毛利润:	$998 722 (67.16 %)
EPS:	$-2.90

FY	2021
营收:	$1.49M
毛利润:	$998 722 (67.16 %)
EPS:	$-2.90

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.471

FY	2019
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.126

Financial Reports:

No articles found.

Statera Biopharma, Inc.

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.